Key result
PBMC Bax and Bcl-2 levels independently predict major cardiovascular events in chronic heart failure.
Why the study?
To investigate Bax and Bcl2 protein expression in PBMC of CHF patients and analyze their value for predicting MACE.
Do Bax and Bcl2 protein expression levels in peripheral blood mononuclear cells predict major adverse cardiovascular events in patients with chronic heart failure?
Observational (n=154)
No
Do Bax and Bcl2 protein expression levels in peripheral blood mononuclear cells predict major adverse cardiovascular events in patients with chronic heart failure?
Bax and Bcl2 protein levels in peripheral blood mononuclear cells can serve as independent predictors for major adverse cardiovascular events in patients with chronic heart failure.
Answers are grounded in this paper and cite their sources.
Bax/Bcl2 levels were associated with MACE in chronic HF; hypothesis-generating and requires prospective validation before any clinical role.
To investigate the expression of Bax and Bcl2 protein in peripheral blood mononuclear cells (PBMC) of patients with chronic heart failure (CHF), and to analyze their value for predicting major adverse cardiovascular event (MACE) in CHF patients. A total of 154 fasting venous blood samples from CHF patients were collected in our hospital from January 2017 to June 2019, and they were divided into 2 group according to whether MACE occurred during 3 years follow-up, MACE group and No-MACE group. Levels of Bax and Bcl2 protein expression in PBMC of CHF patients using enzyme-linked immunosorbent assay (ELISA), and then evaluated the predictive power of Bax and Bcl2 expression for MACE using logistic regression analysis and ROC curve. 62 (40.26%) of 154 CHF patients occurred MACE during follow-up, and there were significant differences in age, diabetes, LVEF, LDL-C and NYHA grade between MACE group and No-MACE group. Levels of Bax protein expression in PBMC of CHF patients in MACE group were significantly higher than those in No-MACE group, while levels of Bcl2 protein expression were significantly lower than those in No-MACE group, and Bax and Bcl2 protein levels increased and decreased with NYHA grades in MACE group and No-MACE group, respectively. Results of univariate and multivariate logistic regression analysis showed that Bax (OR, 1.026; 95% CI, 1.003-1.049; P = .027) and Bcl2 levels (OR, 0.952; 95% CI, 0.908-0.998; P = .041) were independent predictive factors for MACE in CHF patients. In addition, Bax and Bcl2 levels could be used to differentiate CHF patients at risk for MACE with an AUC of 0.744 (95% CI: 0.660-0.827) and an AUC of 0.743 (95% CI: 0.667-0.819), respectively. Levels of Bax and Bcl2 protein in PBMC could be used as independent predictive factors for MACE in CHF patients.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) conducted an observational in Chronic heart failure (n=154). Bax and Bcl2 protein expression in peripheral blood mononuclear cells was evaluated on Major adverse cardiovascular event (MACE) (OR 1.026, 95% CI 1.003-1.049, p=.027). Bax and Bcl2 protein levels in peripheral blood mononuclear cells independently predicted major adverse cardiovascular events in chronic heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: